The Concord Biotech IPO is a 100% offer-for-sale (OFS) of 20,925,652 equity shares by Helix Investment Holdings Pte Ltd. The price band for the IPO is set at ₹705 to ₹741 per share, with a total issue size of ₹1,551 crore. The IPO will open for subscription on August 4, 2023, and close on August 8, 2023.
Concord Biotech is a pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients (APIs). The company has a strong track record in the fermentation-based API segment, and commands a market share of over 20% by volume in this space. Concord Biotech’s products are used in a variety of therapeutic areas, including oncology, cardiovascular, and anti-infectives.
The company is backed by Quadria Capital and Rekha Jhunjhunwala, and has a strong management team with over 30 years of experience in the pharmaceutical industry. Concord Biotech is well-positioned to benefit from the growing demand for APIs in India and other emerging markets.
Here are some key things to know about the Concord Biotech IPO:
- The IPO is priced at ₹705 to ₹741 per share, with a total issue size of ₹1,551 crore.
- The IPO opens for subscription on August 4, 2023, and closes on August 8, 2023.
- The minimum investment amount is ₹14,820 (20 shares).
- The shares will be listed on the BSE and NSE on August 18, 2023.
If you are considering investing in the Concord Biotech IPO, you should carefully consider the risks and rewards involved. The company is facing some challenges, including rising input costs and increasing competition. However, Concord Biotech has a strong track record and a well-positioned business.
Ultimately, the decision of whether or not to invest in the Concord Biotech IPO is a personal one. You should do your own research and consult with a financial advisor before making a decision.